Search

News Role of Transthyretin in the Development of Amyloidosis

Transthyretin (TTR), one of the transport proteins, tends to form extracellular deposits that accumulate in key organs, such as the heart and nerves. The formation of TTR deposits leads to the development of systemic amyloidosis, a disease with highly heterogeneous clinical manifestations. Warning signs may include carpal tunnel syndrome, among others. What is the physiological role of TTR in the body and what role does its structure play in the development of amyloidosis?

Source: Amyloidosis 20. 12. 2022

News Clinical Experiences with Reversing Dabigatran with Idarucizumab

Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.

Source: Anticoagulant Treatment 9. 12. 2021

Články časopisu Encyclopedia of CLL Subsets –⁠ a Unique Bioinformatics Tool and Database for Analysis of Subsets of Stereotypical B-Cell Receptors in CLL

Author of the article: T. Reigl, K. Stránská, V. Bystrý, A. Krejčí, A. Grioni, Š. Pospíšilová, N. Darzentas, K. Plevová Source: Klinická onkologie | Supplementum1/2019 10. 4. 2019

News What Next for Patients with CLL After Stopping Venetoclax?

Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based on venetoclax. However, managing further treatment when venetoclax needs to be discontinued remains a relatively unexplored area without standardized protocols.

Source: Chronic Lymphocytic Leukemia 17. 7. 2020

News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients

A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.

Source: Chronic Lymphocytic Leukemia 8. 6. 2020

News Meta-analysis of Efficacy and Safety of Third-Generation Antiseizure Medications in Adjunctive Treatment of Focal Seizures in Adults with Epilepsy

Epilepsy treatment is primarily symptomatic, aimed at reducing seizure frequency. However, more than 50% of patients do not achieve seizure freedom with monotherapy. Below we summarize the results of a meta-analysis comparing the efficacy and safety of third-generation antiseizure medications in the treatment of focal seizures in adults with epilepsy.

Source: Epilepsy 8. 6. 2023

News Teriflunomide "under the microscope" or what it's like to live with MS in the North

The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical practice in the Nordic countries? What is adherence to this therapy like? And what are its health-economic consequences? We briefly summarize the answers to these questions.

Source: Multiple Sclerosis 12. 1. 2023

News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease –⁠ Prospective ELEGANCE Study

Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.

Source: Parkinson's Disease 22. 11. 2022

News Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma

In mid-2020, the European Commission approved two new fixed combinations of drugs by Novartis for patients with uncontrolled asthma –⁠ the dual combination Atectura® (LABA+ICS) and the triple combination Enerzair® (LABA+LAMA+ICS) for inhalation once daily using the Breezhaler® inhaler.

Source: Asthma under control 28. 1. 2021

News The Position of Lurasidone in Schizophrenia Therapy −⁠ Current Conclusions and Consensus of the Expert Panel

Lurasidone is an antipsychotic belonging to the group of serotonin and dopamine antagonists (SDA) indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. The efficacy of lurasidone has been confirmed by a number of clinical studies, compared to placebo and using active control with known antipsychotics (e.g., olanzapine or quetiapine). The aim of the recently published study was to define current possibilities of using lurasidone in the treatment of schizophrenia and to identify patient groups that would benefit the most from this therapy.

Source: Modern Treatment of Schizophrenia 24. 8. 2021

News Monocyte Distribution Width Indicates Sepsis Regardless of Sepsis Etiology

Patients in intensive care units represent a high-risk population for the development of sepsis, which is one of the primary causes of mortality in these settings. The aim of the recently published study was to evaluate the diagnostic accuracy and prognostic properties of the monocyte distribution width parameter in septic patients.

Source: Because 29. 11. 2021

News Young man with nephrotic syndrome and portal vein thrombus successfully treated with edoxaban −⁠ case report

Venous thrombosis is one of the main complications of nephrotic syndrome (NS), though it is most often located in the renal vein. The following case report describes an adult patient with relapsing corticosteroid-dependent minimal change disease complicated by portal vein thrombosis and subsequent successful treatment with edoxaban.

Source: Atrial Fibrillation 26. 3. 2020

News MDT Board: a unique project for doctors caring for patients with lung diseases and other thoracic pathologies

A unique concept of a cooperative thoracic group has been created in the Czech Republic, involving specialists from several leading Prague clinics. The primary purpose of the so-called board is to provide the best diagnostic and treatment plan for a patient with lung disease and other pathologies in the thoracic area, shared by all members of the multidisciplinary team and based on current knowledge. The MDT Board project, which operates on the principle of online indication seminars, is intended for doctors of patients with common and rare lung diseases.

Source: MDT Board 14. 11. 2022

News Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting

Summary data from several studies were used by the authors of the following analysis to evaluate the efficacy of the intravenous and oral forms of the fixed combination NEPA (netupitant/fosnetupitant + palonosetron) administered with dexamethasone in preventing chemotherapy-induced vomiting based on cisplatin or anthracycline and cyclophosphamide (AC).

Source: Antiemetic Therapy 15. 2. 2021

Články časopisu Use of the KLS Martin Nd:YAG laser MY 40 1.3 in Lung Parenchyma Surgery

Author of the article: J. Vodička, Špidlen V., Klečka J., Šimánek V., Šafránek J. Source: Rozhledy v chirurgii | 5/2009 7. 5. 2009